Literature DB >> 17068285

Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice.

Eva J A van Wanrooij1, Gijs H M van Puijvelde, Paula de Vos, Hideo Yagita, Theo J C van Berkel, Johan Kuiper.   

Abstract

OBJECTIVE: Atherosclerosis is a chronic (auto-)inflammatory disease and T cell activation is an important factor in this process. Tnfrsf4 (OX40) and Tnfsf4 (OX40 ligand) are members of the tumor necrosis factor (TNF) and TNF receptor family and OX40/OX40L mediated signaling is important in co-activation of T cells and facilitates B-T cell interaction. In this study we assessed the role of the OX40/OX40L pathway in atherosclerosis and the effect of interruption of the OX40/OX40L pathway on lesion development. METHODS AND
RESULTS: We treated low-density lipoprotein receptor-deficient (LDLr-/-) mice with an anti-OX40L antibody which lead to a 53% decrease in atherosclerotic lesion formation. Treatment resulted in inhibition of Th2 mediated isotype switching by decreasing interleukin (IL)-4 secretion and subsequent low IgG1 serum levels against oxLDL, whereas protective anti-oxLDL specific IgM titers were increased in treated mice compared with control.
CONCLUSIONS: We conclude that blocking the OX-40/OX40L interaction reduced atherogenesis by inhibition of IL-4 mediated Th2 induced isotype switching and subsequent increased levels of anti-oxLDL IgM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17068285     DOI: 10.1161/01.ATV.0000251007.07648.81

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  37 in total

1.  Mathematical model reveals how regulating the three phases of T-cell response could counteract immune evasion.

Authors:  Tommaso Lorenzi; Rebecca H Chisholm; Matteo Melensi; Alexander Lorz; Marcello Delitala
Journal:  Immunology       Date:  2015-08-02       Impact factor: 7.397

Review 2.  Adaptive immunity in atherogenesis: new insights and therapeutic approaches.

Authors:  Andrew H Lichtman; Christoph J Binder; Sotirios Tsimikas; Joseph L Witztum
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

Review 3.  Genetic and genomic insights into the molecular basis of atherosclerosis.

Authors:  Yaoyu Chen; Jarod Rollins; Beverly Paigen; Xiaosong Wang
Journal:  Cell Metab       Date:  2007-09       Impact factor: 27.287

4.  The upregulated expression of OX40/OX40L and their promotion of T cells proliferation in the murine model of asthma.

Authors:  Wei Lei; Da-Xiong Zeng; Can-Hong Zhu; Gao-Qin Liu; Xiu-Qin Zhang; Chang-Guo Wang; Qin Wang; Jian-An Huang
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

5.  Effects of OX40-OX40L interaction on the nuclear factor of activated T cells c1 in ApoE-deficient mice.

Authors:  Jin-chuan Yan; Liang-jie Xu; Cui-ping Wang; Zhong-qun Wang
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

6.  Genetic variants of TNFSF4 and risk for carotid artery disease and stroke.

Authors:  P S Olofsson; L A Söderström; C Jern; A Sirsjö; M Ria; E Sundler; U de Faire; P G Wiklund; J Ohrvik; U Hedin; G Paulsson-Berne; A Hamsten; P Eriksson; G K Hansson
Journal:  J Mol Med (Berl)       Date:  2008-11-08       Impact factor: 4.599

Review 7.  Inflammation and immune system interactions in atherosclerosis.

Authors:  Bart Legein; Lieve Temmerman; Erik A L Biessen; Esther Lutgens
Journal:  Cell Mol Life Sci       Date:  2013-02-21       Impact factor: 9.261

Review 8.  Innate and adaptive immunity in atherosclerosis.

Authors:  René R S Packard; Andrew H Lichtman; Peter Libby
Journal:  Semin Immunopathol       Date:  2009-05-16       Impact factor: 9.623

9.  ATM gene mutations result in both recessive and dominant expression phenotypes of genes and microRNAs.

Authors:  Denis A Smirnov; Vivian G Cheung
Journal:  Am J Hum Genet       Date:  2008-08       Impact factor: 11.025

Review 10.  Inflammation in atherosclerosis: from pathophysiology to practice.

Authors:  Peter Libby; Paul M Ridker; Göran K Hansson
Journal:  J Am Coll Cardiol       Date:  2009-12-01       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.